Chai Discovery

Antibodies and other biologic drugs are revo­lu­tion­izing medicine, yet the process of screening for effective new biologics is still slow, expensive, and risky. The ability to design molecules that will predictably bind to their targets de novo — without massive exper­i­mental screening — would dramat­i­cally accelerate the process. Chai Discovery is building multimodal, zero-shot generative AI platforms that can design antibodies and other molecules with high binding rates. By creating models that reason at the atomic level, the company aims to shift drug discovery from an era of stochastic screening into an era of intentional, programmable design.